Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
read more
https://www.chimeron.com/wp-content/uploads/2024/06/RECIPIENT-Innovative-Concept-Award.png
900
900
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2024/06/RECIPIENT-Innovative-Concept-Award.png
Harnessing Genetic Medicine & saRNA to Transform Oncology
Developing in vivo CAR, immuno-oncology, and cancer vaccine platforms.
Our Mission
We're dedicated to advancing genetic medicine and transforming cancer treatment. Our groundbreaking technology enables unparalleled gene expression and therapeutic potency, making it ideal for developing enhanced in vivo CAR-T therapies.
Our innovative technology is also catalyzing advancements in immuno-oncology and cancer vaccines -- offering new hope in the battle against cancer.
How we do it
Chimeron Bio's unique approach achieves superior expression and broader dynamic range compared to other leading RNA technologies.
Single Package
Deliver multi-pathway therapies with a single package
Exceptionally Large Payloads
Able to carry exceptionally large RNA payloads, combined with self-amplification to deliver large proteins or multiple proteins
Multiple Gene Delivery
Co-deliver RNA expressing multiple different proteins
Targeted Uptake
Potential for targeted delivery via envelope + ligand of choice
In the News
The Latest from Chimeron Bio
Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
read more
https://www.chimeron.com/wp-content/uploads/2024/06/Chimeron-Finalist-Award-Advance-Biotech-Grant-Award-June-2023.png
750
750
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2024/06/Chimeron-Finalist-Award-Advance-Biotech-Grant-Award-June-2023.png
Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors
read more
https://www.chimeron.com/wp-content/uploads/2023/05/Tony-de-Fougerolles-PhD.png
300
300
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2023/05/Tony-de-Fougerolles-PhD.png
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors
Chimeron Bio Welcomes Kevin Heyeck as New CEO
read more
https://www.chimeron.com/wp-content/uploads/2023/05/MicrosoftTeams-image-78-1.png
300
300
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2023/05/MicrosoftTeams-image-78-1.png
Chimeron Bio Welcomes Kevin Heyeck as New CEO
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
read more
https://www.chimeron.com/wp-content/uploads/2023/05/FUJI.webp
206
206
Chimeron Bio | Redefining Cancer Therapeutics
Chimeron Bio | Redefining Cancer Therapeutics
https://www.chimeron.com/wp-content/uploads/2023/05/FUJI.webp